DaVita to present three abstracts on Peritoneal Dialysis at the ISPD meeting

DaVita Inc. (NYSE: DVA), a leading provider of kidney care services for those diagnosed with chronic kidney disease (CKD), in conjunction with DaVita Clinical Research(R), today announced that it will present three abstracts at the 3rd North American Chapter meeting of the International Society for Peritoneal Dialysis (ISPD) on August 27-29 in Vancouver, British Columbia.

ISPD provides leading renal health care providers with the opportunity to advance their knowledge of peritoneal dialysis (PD) and to promote advancement of such knowledge through international meetings and scientific publications.

The presentations will highlight subjects critical to physicians, nurses and other practitioners in the field of PD, including:

  • A DaVita(R) pilot program evaluating ESA use in PD patients and how to ensure patient adherence while maintaining hemoglobin outcomes;
  • Access to Peritoneal Dialysis: Overcoming Obstacles for Uninsured, Unencountered Patients - a look at how changes in PD clinic infrastructure and the industry's perception would increase usage of this valuable treatment method;
  • The Post-Peritonitis Checklist: Beyond Pharmacological Treatment - an analysis of the impact implementing a step-by-step checklist of pre-existing and innovative interventions into patient care practices resulted in reduced peritonitis rates.

"DaVita is committed to leading the renal community in seeking out new and innovative ways to improve clinical outcomes for patients with kidney disease," said Allen R. Nissenson MD, Chief Medical Officer at DaVita. "The three abstracts being presented at this meeting reflect DaVita's success in driving quality improvement for patients."

DaVita and DaVita Clinical Research are registered trademarks of DaVita Inc. All other trademarks are the property of their respective owners.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New FDA award fuels research into autosomal dominant tubulointerstitial kidney disease